Sun Pharma Receives EIR for Halol Facility
Sun Pharmaceutical Industries Ltd. has announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat) during the period February 12-23, 2018. The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed. “This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally,” Mr. Dilip Shanghvi, Managing Director, Sun Pharma said on the development.

Dilip Shanghvi
Looking for chemical products? Let suppliers reach out to you!
2026-07-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Red Sun: The company is committed to supply 97% Chlorantraniliprole technical no less than 1000 tons to Sino-Agri this year
-
China丨The first phase of Red Sun's digital transformation project launched
-
Sun Pharma announces licensing agreement with CSIR-IICT
-
New Location, New Horizon: ECHEMI Thailand Branch Embarks on a New Chapter
-
ICIS Global No.58: ECHEMI Again Ranks Among the World’s Chemical Distributors
-
Notice of 2026 Chinese New Year Holiday
-
Supporting Each Other | ECHEMI Employees Voluntarily Raise Funds for Flood Relief in Southern Thailand
-
International Workers' Day Holiday Notice and Service Arrangement
-
Address Change Declaration(ECHEMI SPECIALTIES)
-
China’s API Export Shift Takes Center Stage at API China 2026
Recommend Reading
-
Röhm Launches New Sulfuric Acid Plant
-
NOVA Chemicals Launches PE Resins with Next-Generation Non-Fluoropolymer Processing Aid
-
Polyethylene Narrowly Ranges Since August
-
BASF Zhanjiang Integrated Base Acrylate Project Mechanically Completed
-
"Golden September Fails to Appear" Shandong Normal Butanol Prices Decline in September